The Beijing drug company lost 60% of its market to AstraZeneta, the $2 billion cardiovascular drug.

Pharmaceutical Network September 11th, a few days ago, Beijing four ring Cobao pharmaceutical non-Lodi flat release tablets to copy 4 categories of filing applications for listing was accepted.
in 2019, China's public medical institutions terminal non-Lodi tablet sales of more than 2 billion yuan, of which AstraZeneta market share accounted for the largest, 58.73 percent.
data show that the non-Lodi flat release tablets are calcium disophate channel antagonists (calcium channel blockers) for the treatment of hypertension (can be used alone or in combination with other antihypertensive drugs).
non-Lodi flat release tablets were developed by AstraZenecon Pharmaceuticals Ltd. and listed in the United States in 1991.
In recent years, China's public medical institutions terminal non-Lodi tablet sales (units: 100 million yuan) Source: Minet China's public medical institutions terminal competition pattern Mi intranet data show that in 2019 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal non-Lodi tablet sales of more than 2 billion yuan.
, AstraZeneta has the largest market share, followed by Hefei Cube Pharmaceuticals and Changzhou Four Pharmaceuticals, with a market share of more than 10%.
it is worth noting that AstraZeneta's market share has fallen from 69.23 per cent in 2017 to 58.73 per cent in 2019, following the rapid growth of domestic pharmaceutical companies in recent years.
source: Mi Net one-click search non-Lodi flat release tablets have AstraZeneta, Changzhou four pharmaceutical, Nanjing Yiheng Pharmaceutical and other 5 production enterprises, so far, the product has not been approved by enterprises through the consistent evaluation.
Prior to this, the non-Loddi ping slow release tablets have been Tianjin Tiansli Sant Pharmaceuticals, Ling wanzhou International Pharmaceuticals to copy 4 categories of declaration and listing, is currently in the review and approval (in the drug review center), after approval will be treated as a review.
source: MED2.0 China Drug Review Database Source: CDE official website, Minet database.